comelofion befween Sloofamiry profeins and menal cell carcinoma Pospibility of early diagnsis and malecular targeeing therapy

点击翻译按钮获取中文摘要

This study aimed to analyze expression of S100A10, anneal II and brain-type fatty acid binding protein (B-FABP) genes in renal cell carcinoma (RCC) and their potential value as tumor markers and molecular targeting therapy. Expression of each gene or protein in the tumor than that in the normal tissues was significantly increased In the tissue sections of RCC, S100A10 and annexin If were immunostained in membranes. In the normal renal epithelia, however, both antigens were stained in the Bowman's capsule and the tubules from Henle's loop through the collecting duct system, but not in the proximal tubules, from where most RCC are derived We decided that both antigens was not suitable as a candidate for molecular targeting therapy. Interestingly, S100A10 and annexin If were stained in all RCC sections regardless of nuclear grade and stage. This result allowed us to discuss that except for tumor invasion and metastasis, they also have the possibility of angiostatin. We am further required for new approachNo B-FABP was immunohistochemically detected in normal kidney sections, but it was stained in the cytoplasm of ACC tissue sections. The carcinoma tissues but not the noncancerous parts of the kidney samples resected from patients with RCC expressed the transcript Zr B-FABP. Furthermore the B-FABP cDNA fragment as well as S100A10 was not amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) in the urine samples of healthy donors or patients with RCC after surgical operation. However, B-FABP cDNA was amplified in the patient's urine samples collected before surgery. The minimum urine sample volume in RT-PCR is 500 uLIn conclusion, B-FABP is a novel marker and S100A10 is also promising marker Zr RCC. We would provide the new detection kit of RCC from urine using immunochromatography.